Blockbuster GLP-1 medications like Ozempic and Mounjaro might sharpen your figure, but they could also cloud your vision in ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
2d
Daily Express US on MSNOzempic and Zepbound linked to rare eye conditions that could cause blindnessA new study suggests popular weight-loss drugs like Ozempic and Zepbound may be linked to rare eye conditions that could ...
Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on UnitedHealth (UNH – Research Report) and Eli ...
Eli Lilly and Company has announced the appointment of Winselow Tucker as President and General Manager for Lilly India, ...
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect. Eli Lilly missed analysts’ revenue expectations by 6% last quarter ...
Eli Lilly and Company (Lilly) announced the appointment of Winselow Tucker as president and general manager for Lilly India, effective immediately.
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results